A priority goal for next-generation COVID-19 vaccines is to reduce infection with and transmission of SARS-CoV-2 via the respiratory route, while maintaining or enhancing protection against symptomatic and severe disease. Utilization of mucosal vaccination to elicit robust mucosal immunity in the respiratory tract is a logical approach to achieving these goals.
Read More
View All News
USSF collaboration (VaxForm) amongst the select few on list of nextgen SARS-CoV-2 mucosal vaccine candidates in use or in clinical development.
April 12, 2023
Written by
GamePlanX Network of Experts
Specializing in pharmaceutical manufacturing, regulatory‑compliant digital marketing, and healthcare industry growth strategies. This multidisciplinary team provides subject‑matter expertise relevant to USSF’s cGMP operations, botanical injectables, and clinical education initiatives.
